Non-small cell lung cancer frequently spreads to the central nervous system (CNS), but patients with CNS metastases may be excluded from clinical trials of new drugs. A University of Colorado Cancer Centerstudy
being presented at the 16th World Conference on Lung Cancer
reveals the full extent to which the CNS may be under-explored in clinical research.
The study combed the website ClinicalTrials.gov to identify 413 open lung cancer clinical trials. Overall, 41 percent of trials only included patients if their CNS disease was previously treated. Twenty-six percent allowed in patients with CNS involvement and no previous treatment. Fourteen percent excluded all patients with a history of brain spread and nineteen percent of trials did not comment on any criteria related to CNS disease at all.